Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial https://www.medrxiv.org/content/10.1101/2021.04.10.21254672v1 ISRCTN86534580- The trial opened on April 2, 2020. Randomization to inhaled budesonide began on November 27, 2020 and… Continue reading "(13 Apr 2021) Budesonide- reduced time to recovery by a median of 3 days"
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial https://doi.org/10.1016/S2213-2600(21)00160-0 NCT04416399-146 participants were randomly assigned-73 to usual care and 73 to budesonide. For the per-protocol population (n=139), the primary outcome occurred in ten… Continue reading "(13 Apr 2021) Budesonide- early administration of inhaled budesonide reduced time to recovery"
Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial https://www.medrxiv.org/content/10.1101/2021.02.04.21251134v1 NCT04416399- 146 patients underwent randomisation. For the per protocol population (n=139), the primary outcome occurred in 10 participants and 1 participant in the usual care… Continue reading "(08 Feb 2021) Budesonide- inhaled budesonide reduced time to recovery"
